Avalon GloboCare (ALBT) Stock Price, News & Analysis

Company Overview

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

Key Stats

• Today's Range: $4.75 to $4.95
• 50-Day Range: $3.28 to $10.90
• 52-Week Range: $2.11 to $21.60
• Volume: 20,005 shs
• Average Volume: 512,435 shs
• Market Capitalization: $5.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Avalon GloboCare Stock Analysis - MarketRank™

Avalon GloboCare scored higher than 32% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Avalon GloboCare.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Avalon GloboCare is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Avalon GloboCare is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.62% of the float of Avalon GloboCare has been sold short.

Short Interest Ratio / Days to Cover

Avalon GloboCare has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Avalon GloboCare has recently decreased by 47.58%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avalon GloboCare does not currently pay a dividend.

Dividend Growth

Avalon GloboCare does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.06

Percentage of Shares Shorted

5.62% of the float of Avalon GloboCare has been sold short.

Short Interest Ratio / Days to Cover

Avalon GloboCare has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Avalon GloboCare has recently decreased by 47.58%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.35

News Sentiment

Avalon GloboCare has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Avalon GloboCare this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for ALBT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Avalon GloboCare to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Avalon GloboCare insiders have not sold or bought any company stock.

Percentage Held by Insiders

37.30% of the stock of Avalon GloboCare is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 1.42% of the stock of Avalon GloboCare is held by institutions.

ALBT Stock Analysis - Frequently Asked Questions

How have ALBT shares performed this year?

Avalon GloboCare's stock was trading at $3.26 at the beginning of 2025. Since then, ALBT stock has increased by 47.2% and is now trading at $4.80.
View the best growth stocks for 2025 here.

How were Avalon GloboCare's earnings last quarter?

Avalon GloboCare Corp. (NASDAQ:ALBT) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($1.82) earnings per share (EPS) for the quarter. The business had revenue of $0.35 million for the quarter.

When did Avalon GloboCare's stock split?

Avalon GloboCare shares reverse split on Monday, October 28th 2024. The 1-15 reverse split was announced on Thursday, October 24th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Avalon GloboCare?

Shares of ALBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Avalon GloboCare own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Avalon GloboCare investors own include Sangamo Therapeutics (SGMO), Ford Motor (F), Pfizer (PFE), Plug Power (PLUG), NVIDIA (NVDA), Mullen Automotive (MULN) and Intel (INTC).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 4/03/2025
• Next Earnings (Estimated): 4/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALBT
• Previous Symbol: NASDAQ:AVCO
• CIK: 1630212
• Web: www.avalon-globocare.com
• Phone: (732) 780-4400
• Fax: 732-780-5600
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($19.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-16,710,000.00
• Net Margins: -1,125.59%
• Pretax Margin: -1,125.59%
• Return on Equity: N/A
• Return on Assets: -73.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.11
• Quick Ratio: 0.11

Sales & Book Value

• Annual Sales: $1.31 million
• Price / Sales: 4.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($17.22) per share
• Price / Book: -0.28

Miscellaneous

• Outstanding Shares: 1,094,000
• Free Float: 686,000
• Market Cap: $5.25 million
• Optionable: Not Optionable
• Beta: -0.10